192 related articles for article (PubMed ID: 7673727)
21. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
Müerköster S; Wachowski O; Zerban H; Schirrmacher V; Umansky V; Rocha M
Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
[TBL] [Abstract][Full Text] [Related]
22. Plasmodium yoelii in mice: antigen reactivity of CD4- and CD8-bearing T cells.
Lucas B; Engel A; Camus D; Haque A
Cell Immunol; 1993 Aug; 150(1):59-71. PubMed ID: 8102089
[TBL] [Abstract][Full Text] [Related]
23. Dissection of the functions of antigen-presenting cells in the induction of T cell activation.
Roska AK; Lipsky PE
J Immunol; 1985 Nov; 135(5):2953-61. PubMed ID: 3876370
[TBL] [Abstract][Full Text] [Related]
24. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells.
Beissert S; Hosoi J; Grabbe S; Asahina A; Granstein RD
J Immunol; 1995 Feb; 154(3):1280-6. PubMed ID: 7822797
[TBL] [Abstract][Full Text] [Related]
25. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.
Parajuli P; Pisarev V; Sublet J; Steffel A; Varney M; Singh R; LaFace D; Talmadge JE
Cancer Res; 2001 Nov; 61(22):8227-34. PubMed ID: 11719454
[TBL] [Abstract][Full Text] [Related]
26. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
[TBL] [Abstract][Full Text] [Related]
27. Epidermal cell presentation of tumor-associated antigens for induction of tolerance.
Tan KC; Hosoi J; Grabbe S; Asahina A; Granstein RD
J Immunol; 1994 Jul; 153(2):760-7. PubMed ID: 7912706
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive phenotypic analysis of the gut intra-epithelial lymphocyte compartment: perturbations induced by acute reovirus 1/L infection of the gastrointestinal tract.
Bharhani MS; Grewal JS; Peppler R; Enockson C; London L; London SD
Int Immunol; 2007 Apr; 19(4):567-79. PubMed ID: 17369189
[TBL] [Abstract][Full Text] [Related]
29. NK cells from mammary tumor bearing mice do not exert natural killer activity but function as antibody dependent cellular cytotoxicity effectors.
Rivera LM; Lopez DM
Anticancer Res; 1993; 13(1):177-84. PubMed ID: 8476211
[TBL] [Abstract][Full Text] [Related]
30. Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms.
Watson GA; Fu YX; Lopez DM
J Leukoc Biol; 1991 Feb; 49(2):126-38. PubMed ID: 1991996
[TBL] [Abstract][Full Text] [Related]
31. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
Yamamoto N; Zou JP; Li XF; Takenaka H; Noda S; Fujii T; Ono S; Kobayashi Y; Mukaida N; Matsushima K
J Immunol; 1995 Mar; 154(5):2281-90. PubMed ID: 7868900
[TBL] [Abstract][Full Text] [Related]
32. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
Blazar BR; Jenkins MK; Taylor PA; White J; Panoskaltsis-Mortari A; Korngold R; Vallera DA
J Immunol; 1997 Dec; 159(12):5821-33. PubMed ID: 9550378
[TBL] [Abstract][Full Text] [Related]
33. Alloantigen presentation by individual clones of mouse splenic macrophages. Selective expression of IL-1 alpha in response to CD8+ T cell-derived IFN-gamma defines the alloantigen-presenting phenotype.
McCormack JM; Askew D; Walker WS
J Immunol; 1993 Nov; 151(10):5218-27. PubMed ID: 8228220
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
Rock KL; Clark K
J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
[TBL] [Abstract][Full Text] [Related]
35. Dysfunction of Ia-positive antigen-presenting cells in tumor-bearing mice.
Yamashita U
Jpn J Cancer Res; 1987 Mar; 78(3):261-9. PubMed ID: 3106282
[TBL] [Abstract][Full Text] [Related]
36. Splenic alterations during mammary tumorigenesis: diverse effects on different immune parameters.
Paul RD; Ghaffar A; Sigel MM; Charyulu V; Lopez DM
Anticancer Res; 1981; 1(2):63-9. PubMed ID: 6214206
[TBL] [Abstract][Full Text] [Related]
37. Antigen presentation by dendritic cells focuses T cell responses against immunodominant peptides: studies in the hen egg-white lysozyme (HEL) model.
Gapin L; Bravo de Alba Y; Casrouge A; Cabaniols JP; Kourilsky P; Kanellopoulos J
J Immunol; 1998 Feb; 160(4):1555-64. PubMed ID: 9469410
[TBL] [Abstract][Full Text] [Related]
38. Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T lymphocytes and macrophages.
Elgert KD; Farrar WL
J Immunol; 1978 Apr; 120(4):1345-53. PubMed ID: 305939
[TBL] [Abstract][Full Text] [Related]
39. Macrophages induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses.
Desmedt M; Rottiers P; Dooms H; Fiers W; Grooten J
J Immunol; 1998 Jun; 160(11):5300-8. PubMed ID: 9605128
[TBL] [Abstract][Full Text] [Related]
40. Increased sensitivity of tumor-bearing host macrophages to interleukin-10: a counter-balancing action to macrophage-mediated suppression.
Alleva DG; Burger CJ; Elgert KD
Oncol Res; 1994; 6(4-5):219-28. PubMed ID: 7841545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
